Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.

"J.H., N.F.G., R.H. and S.S. received a grant from Sanofi Pasteur to conduct this study. J.H. received personal fees from Merck Sharp & Dohme, Johnson & Johnson, DKSH Malaysia, Nestle Malaysia, Ferring Pharmaceuticals, Sanofi Malaysia, Zuellig Pharma Malaysia, Abex Medical Systems, Abbott Malaysia and Bayer Malaysia; S.S. received personal fees from Dutch Lady during the 36 months before submitting this manuscript, outside the submitted work. C.M., C.V., C.Z., M.-L.T. and S.M. are employees of Sanofi Pasteur. The other authors have no conflicts of interest to disclose."

"The authors thank the Director General of Health Malaysia for his permission to publish this manuscript. The authors wish to thank the participants and their parents, the investigators, coordinators and study teams. Editorial assistance with the preparation of the manuscript was provided by Annick Moon, PhD and Juliette Gray, PhD, inScience Communications, Springer Healthcare Ltd, London, United Kingdom. Funding for this assistance was provided by Sanofi Pasteur. The authors would like to thank Roopsha Brahma, PhD, for editorial assistance and manuscript coordination on behalf of Sanofi Pasteur. The authors thank the Director General of Health Malaysia for his permission to publish this manuscript. The authors wish to thank the participants and their parents, the investigators, coordinators and study teams. Editorial assistance with the preparation of the manuscript was provided by Annick Moon, PhD and Juliette Gray, PhD, inScience Communications, Springer Healthcare Ltd, London, United Kingdom. Funding for this assistance was provided by Sanofi Pasteur. The authors would like to thank Roopsha Brahma, PhD, for editorial assistance and manuscript coordination on behalf of Sanofi Pasteur."